# Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

> **NCT03575598** · EARLY_PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 10 (actual)

## Conditions studied

- Squamous Cell Carcinoma, Head And Neck
- Squamous Cell Carcinoma Mouth
- Squamous Cell Carcinoma of the Oral Cavity

## Interventions

- **DRUG:** Sitravatinib
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03575598
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-30
- **Primary completion:** 2020-02-18
- **Final completion:** 2020-02-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575598, "Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03575598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*